Vimarsana
Biggest News Aggregation in the World

Page 11 - Solid Biosciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Solid Biosciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Solid Biosciences Today - Breaking & Trending Today

Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates - Vimarsana News

Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates

Anika (ANIK) delivered earnings and revenue surprises of 44.12% and 9.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Source: yahoo.com
Tottenham Owner Joe Lewis Charged with Insider Trading in the US - Vimarsana News

Tottenham Owner Joe Lewis Charged with Insider Trading in the US

Joe Lewis, the owner of Tottenham Hotspur football team, is facing charges of insider trading brought by US prosecutors. The billionaire is accused of sharing stock tips with employees, friends, and romantic partners, leading to 16 counts of securities fraud and three counts of conspiracy for alleged crimes committed between 2013 and 2021. The 86-year-old |

Paramours, Pilots and a Poker Pal: Longtime Tottenham Owner Allegedly Shared Ins - Vimarsana News

Paramours, Pilots and a Poker Pal: Longtime Tottenham Owner Allegedly Shared Ins

Joe Lewis, the 86-year-old billionaire whose family trust now controls the English soccer team, is a defendant in New York

Paramours, Pilots and a Poker Pal: Longtime Tottenham Owner Allegedly Shared Insider-Trading Tips - Vimarsana News

Paramours, Pilots and a Poker Pal: Longtime Tottenham Owner Allegedly Shared Insider-Trading Tips

Joe Lewis, the 86-year-old billionaire whose family trust now controls the English soccer team, is a defendant in New York

Source: wsj.com
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated - Biogen (NASDAQ:BIIB) - Vimarsana News

Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated - Biogen (NASDAQ:BIIB)

Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of